(R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis (Q40269287)

19 September 2017

(R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis (English)

1 reference

19 September 2017

1 reference

Judit Ribas

1

1 reference

19 September 2017

Jacint Boix

series ordinal

2

1 reference

19 September 2017

Laurent Meijer

series ordinal

3

1 reference

19 September 2017

language of work or name

English

0 references

publication date

1 July 2006

1 reference

Experimental Cell Research

19 September 2017

1 reference

19 September 2017

312

1 reference

19 September 2017

12

1 reference

19 September 2017

2394-2400

1 reference

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

19 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.04.021

Amplification of a gene encoding a p53-associated protein in human sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.04.021

The p53-mdm-2 autoregulatory feedback loop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.04.021

Recent progress in the discovery and development of cyclin-dependent kinase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.04.021

Clinical anticancer drug development: targeting the cyclin-dependent kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.04.021

Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.04.021

Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.04.021

Cell differentiation, caspase inhibition, and macromolecular synthesis blockage, but not BCL-2 or BCL-XL proteins, protect SH-SY5Y cells from apoptosis triggered by two CDK inhibitory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.04.021

Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.04.021

The prevention of the staurosporine-induced apoptosis by Bcl-X(L), but not by Bcl-2 or caspase inhibitors, allows the extensive differentiation of human neuroblastoma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.04.021

Stress-induced p53 runs a transcription-independent death program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.04.021

The transcriptional targets of p53 in apoptosis control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.04.021

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.04.021

A small molecule-kinase interaction map for clinical kinase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.04.021

Roscovitine targets, protein kinases and pyridoxal kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.04.021

Activation of p53 by roscovitine-mediated suppression of MDM2 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.04.021

Nuclear accumulation of p53 following inhibition of transcription is not due to diminished levels of MDM2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.04.021

Intra-S-phase checkpoint activation by direct CDK2 inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.04.021

10.1016/J.YEXCR.2006.04.021

7 January 2021

Identifiers

DOI

1 reference

19 September 2017

1 reference